| Literature DB >> 27923829 |
Haseeb Zubair1, Shafquat Azim1, Sanjeev Kumar Srivastava1, Aamir Ahmad1, Arun Bhardwaj1, Mohammad Aslam Khan1, Girijesh Kumar Patel1, Sumit Arora1, James Elliot Carter2, Seema Singh1,3, Ajay Pratap Singh4,3.
Abstract
Aberrant expression of the kinase IKKε in pancreatic ductal adenocarcinoma (PDAC) has been associated with poor prognosis. In this study, we define a pathobiologic function for IKKε in reprogramming glucose metabolism and driving progression in PDAC. Silencing IKKε in PDAC cells, which overexpressed it endogenously, was sufficient to reduce malignant cell growth, clonogenic potential, glucose consumption, lactate secretion, and expression of genes involved in glucose metabolism, without impacting the basal oxygen consumption rate. IKKε silencing also attenuated c-Myc in a manner associated with diminished signaling through an AKT/GSK3β/c-MYC phosphorylation cascade that promoted MYC nuclear accumulation. In an orthotopic mouse model, IKKε-silenced PDAC exhibited a relative reduction in glucose uptake, tumorigenicity, and metastasis. Overall, our findings offer a preclinical mechanistic rationale to target IKKε to improve the therapeutic management of PDAC in patients. Cancer Res; 76(24); 7254-64. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27923829 PMCID: PMC5161695 DOI: 10.1158/0008-5472.CAN-16-1666
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701